VapN would generally be less potent than VapA in membrane disordering, as reflected in experimental CF release but, on the other hand, it is strong enough to reduce phagosome and lysosome acidification (Fig. 1D and Fig. 3D), demonstrating its ability to induce permeability increases in vivo. Here, VAPA is linked to cystic fibrosis.